Clay Siegall holds a B.S in Zoology from the University of Maryland and a PHD in genetics from George Washington University. In 1998 , he founded Seattle Genetics as the company president. He was also the chairman of the Board of Directors and the chief executive officer.
It should be noted that under his leadership, the company has established multiple channels of anti-body based cancer therapies. Seattle Genetics managed to make the longest strides under his leadership more than under any other executive in the recent past.
Dr. Clay has guided the company’s fund raising activities that have seen the company raise more than $675 million via public and private funding. He has also served with various companies such as Bristol-Myers Squibb Pharmaceutical Research Institute, National Cancer Institute and the National Institutes of health.
Seattle Genetics is the supreme biotech firm in the region. Its headquarter is made of a green triangular sculpture made of Lego bricks that act as a simplified replica of a human antibody. Throughout its time, the company has been devoted to researching and controlling the antibodies and also packaging them into drugs.
The company boasts of many employees that have all been working hard to anchor the company through the prevailing challenges in the health sector and ensure it succeeds in its fight against all cancer related issues.These grand ambitions by the company and its membersmay sore the company to greater heights such as growing to become a pharmaceutical company.
Under the leadership of Mr.Clay Siegall, the company has developed a forerunner drug known as Adcetris. It helps in treating Hodgkin lymphoma, a cancer of the lymph system that can advance to other organs of the body. Mr. Clay aspires to move the company beyond focusing on drug development to handling all the difficulties of worldwide marketing of the newer drugs.
He declares the company is emerging globally and turning to a multiproduct-oriented company. It has made numerous sales throughout the business cycles and also opened multiple branches in different parts of the world’s courtesy of one Clay Siegall.
Food and Drug administration has approved the drug to treat lymphoma. Out of its 11 drugs, four attract a great potential for fast sales. Despite of the worrying economic and political climates, Clay stands strong and hopeful for the success of the activities of the company. The company continues to find for long time solutions and positive treatments for cancer and its complications.